Focusing on social processes contributing to marginalization can help clinicians and policy makers mitigate food insecurity risk through improved patient-centered care.
AMA J Ethics. 2018;20(10):E941-947. doi:
10.1001/amajethics.2018.941.
Produce prescription programs can expand patient's food choices and provide financial incentives to change consumption behaviors. If these programs are not linked to established government assistance programs, however, growers could be at risks for bearing the cost.
AMA J Ethics. 2018;20(10):E960-973. doi:
10.1001/amajethics.2018.960
During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts.
AMA J Ethics. 2020;22(1):E5-9. doi:
10.1001/amajethics.2020.5.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Lauren C. Nigro, MD, Michael J. Feldman, MD, Robin L. Foster, MD, and Andrea L. Pozez, MD
Suspected child abuse cases can be identified and repeat hospitalizations of such cases prevented using multidisciplinary teams to evaluate pediatric burns.
AMA J Ethics. 2018;20(6):552-559. doi:
10.1001/journalofethics.2018.20.6.org1-1806.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”